California's Quidel picked up FDA clearances for two infectious disease tests that run on Life Technologies' diagnostics platform, and the two companies are partnering up to spread the assays around the globe.
The deal is done. Diagnostic test maker Quidel now officially owns BioHelix, a Beverly, MA maker of nucleic acid technology for molecular diagnostic tests. Quidel is paying $10 million in cash up front, plus more money depending on a number of development and sales milestones.
Quidel has its latest molecular diagnostic test approval in hand, this time a CE mark for a blood test that screens for herpes plus a virus that causes chicken pox and shingles.
Quidel won a coveted 510(k) clearance from the FDA for a new hand-held molecular diagnostic test to detect DNA for Clostridium difficile bacteria.
Quidel ($QDEL) has received the CE mark for its first molecular diagnostic test, the Influenza A+B real-time RT-PCR assay. The CE mark allows for the launch of the open box molecular platform in